GlassScriptPhysician profile
Ellen Kathleen Porter
NPI 1881625705
$1,971.46
in general payments reported to CMS, 2019-2025
14 companies · $829 in 2025
The $829 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $210 · 2022: $31.70 · 2024: $900 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,721 · Education: $9.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,720.52 |
| Education | $9.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $427.50 | 2021-2025 | |
| Janssen Biotech, INC. | $390.34 | 2021-2025 | Tremfya, Stelara |
| Fujifilm Healthcare Americas Corporation | $250.00 | 2024 | Utaswako Afp-L3 |
| Takeda Pharmaceuticals U.S.A., INC. | $249.11 | 2021-2025 | Entyvio, Gattex |
| Phathom Pharmaceuticals, INC. | $187.09 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $160.95 | 2025 | Iqirvo |
| Ardelyx, INC. | $105.86 | 2025 | Ibsrela |
| Pfizer INC. | $87.88 | 2021-2025 | |
| Genzyme Corporation | $38.50 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.52 | 2025 | Xifaxan |
| Ferring Pharmaceuticals INC. | $16.41 | 2021 | |
| Intercept Pharmaceuticals, INC. | $15.58 | 2021 | |
| Celltrion USA INC. | $13.48 | 2024 | Vegzelma |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.